PGP (ABCB1)
|
Ubiquitous; high in liver, kidney, gut, brain, testis, placenta |
Apical |
Numerous xenobiotics, large lipophilic cations or uncharged compounds |
Involved in multidrug resistance |
MDR2 (ABCB4)
|
Liver |
Apical |
Phosphatidylcholine,cholesterol |
Mutations lead to PFICa type 3 |
BSEP (ABCB11)
|
Liver, placenta |
Apical |
Bile acids, limited xenobiotic transport |
Mutations lead to PFIC type 2 |
MRP1 (ABCC1)
|
Ubiquitous, low in liver |
Basolateral |
Amphipathic organic anions, lipophilic drugs and glutathione, sulfate or glucuronate-conjugated compounds |
Involved in multidrug resistance |
MRP2 (ABCC2)
|
Liver, gut, kidney, brain,placenta, gall bladder |
Apical |
Many drugs, bile acids, bilirubin, leukotriene, glucuronide and glutathione conjugates |
Involved in multidrug resistance; mutations lead to Dubin-Johnson syndrome |
MRP3 (ABCC3)
|
Liver, gut, brain, kidney, prostate, pancreas, gall bladder, lung and placenta |
Basolateral |
Bile acids, bilirubin, 17β-glucuronosyl estradiol, leukotriene, glucuronide conjugates of drugs |
Expression is induced in Dubin-Johnson patients and during cholestasis |
BCRP (ABCG2)
|
Placenta, liver, kidney, intestine, brain |
Apical |
Numerous drugs, particularly antineoplastics, estrogen |
Involved in multidrug resistance |
OATP1 (SLC21a1)
|
Liver, kidney, brain, lung, colon |
Basolateral |
Bromosulfophthalein, bile acids, steroids, eukotriene |
Bi-directional transport; Mediates sodium-independent bile acid uptake |
OATP2 (SLC21a5)
|
Liver, kidney, brain, retina, heart, lung, spleen, skeletal muscle, testis |
Basolateral |
Many anionic compounds, estrogen, bilirubin, steroids, bile acids, glucuronide conjugates, GSH |
Bi-directional transport; mediates sodium-independent bile acid upake |
NTCP (SLC10a1)
|
Liver |
Basolateral |
Conjugated bile salts, estrone-3-sulfate, dehydroepiandrosterone sulfate, bromo-sulfophthalein |
Mediates sodium-dependent bile acid uptake |